Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Continued generic erosion impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb
 
2Q Revenues: $4.0 billion (-9%)
 
2Q Earnings: $536 million (-17%)
 
YTD Revenues: $7.9 billion (-19%)
 
YTD Earnings: $1.1 billion (-34%)
 
Comments: U.S. sales decreased 22% to $2.0 billion in the quarter and international sales increased 10% to $2.0 billion. Due to continued generic erosion, Abilify sales declined 21% to $563 million in the quarter, Plavix sales dropped 94% to $44 million, and Avapro/Avalide sales were down 52% to $56 million. Baraclude sales were $371 million, up 4%. Reyataz sales were $431 million, up 6%. Sustiva Franchise sales were up 6% to $411 million. Sprycel sales were up 28% to $312 million. Yervoy sales were up 44% to $233 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters